CIPROFLOXACIN INJECTION SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

CIPROFLOXACIN (CIPROFLOXACIN LACTATE)

から入手可能:

BAXTER CORPORATION

ATCコード:

J01MA02

INN（国際名）:

CIPROFLOXACIN

投薬量:

2MG

医薬品形態:

SOLUTION

構図:

CIPROFLOXACIN (CIPROFLOXACIN LACTATE) 2MG

投与経路:

INTRAVENOUS

パッケージ内のユニット:

100ML/200ML

処方タイプ:

Prescription

治療領域:

QUINOLONES

製品概要:

Active ingredient group (AIG) number: 0123207007; AHFS:

認証ステータス:

DORMANT

承認日:

2018-07-06

製品の特徴

_CIPROFLOXACIN INJECTION _
_ _
_Page 1 of 62 _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CIPROFLOXACIN
INJECTION
CIPROFLOXACIN 0.2 % INTRAVENOUS INFUSION
CIPROFLOXACIN 0.2 % (AS LACTATE) IN 5 % DEXTROSE SOLUTION
STERILE
ANTIBACTERIAL AGENT
Baxter Corporation
Mississauga, Ontario
L5N 0C2
Date of Revision:
June 3, 2019
SUBMISSION CONTROL NUMBER: 224895
_CIPROFLOXACIN INJECTION _
_ _
_Page 2 of 62 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
3
SUMMARY PRODUCT INFORMATION
.......................................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................................
3
CONTRAINDICATIONS
..................................................................................................................
5
WARNINGS AND PRECAUTIONS
................................................................................................
6
PRECAUTIONS
...............................................................................................................................
10
ADVERSE REACTIONS
................................................................................................................
15
DRUG INTERACTIONS
.................................................................................................................
18
DOSAGE AND ADMINISTRATION
.............................................................................................
24
OVERDOSAGE
...............................................................................................................................
26
ACTION AND CLINICAL PHARMACOLOGY
...........................................................................
27
STORAGE AND STABILITY
........................................................................................................
32
SPECIAL HANDLING INSTRUCTIONS
......................................